Clayton D. Harro, M.D., Sc.M.
Co-PI, Project 4
Bloomberg School of Public Health
Disease Prevention and
Center and Institute
Center for Immunization
School of Public Health
Is board certified in
Internal Medicine, and received his Master of Science degree in
Vaccine Development, Evaluation, and Policy at the Johns Hopkins
University School of Hygiene and Public Health in 1996. His Masters
thesis focused on DNA vaccines and included a protocol design for an
outpatient vaccination/inpatient challenge study of an
investigational DNA influenza vaccine.
Since joining the Johns
Hopkins University Center for Immunization Research (CIR) in 1996,
Dr. Harro has been principal investigator (PI) on industry-sponsored
studies of preventive HIV vaccines, DNA influenza vaccines,
hepatitis B vaccines with MF59, and hepatitis B vaccines with GM-CSF.
He has also served as medical director of the Johns Hopkins AIDS
Vaccine Evaluation Unit. In this capacity, he has been the site PI
on all preventive AIDS vaccine studies at the CIR and has actively
participated in the design, conduct, and medical oversight of phase
I, II, and III trials of recombinant subunit vaccines, and phase
I/II trials of vector-based vaccines using vaccinia, canarypox, and
attenuated S. typhi. In addition, Dr. Harro has collaborated with
the National Cancer Institute (NCI) to develop a vaccine to prevent
cervical cancer. He designed and was PI on the first-ever phase I
and phase II vaccine trials for human papillomavirus (HPV) type 16
virus-like particle (VLP) vaccines.
preventive HIV vaccines, HPV human papillomavirus vaccines,
hepatitis B vaccines